"It is particularly noteworthy that MSI-1436 stimulates tissue regeneration in both zebrafish and adult mice, two widely divergent species that are separated by approximately 450 million years of evolution."
Also paper explained that the drug had been applied in Phase 1 clinical trials with humans as a treatment for diabetes and obesity.
"Importantly, the doses we have shown to be effective in stimulating tissue regeneration are 5–50-times lower than the maximum well-tolerated human dose."
Dep nding on how complex the molecule is sometimes they won't even be able to make it . More than the half the group buys on that specific longevity forum failed
Failed as in it was too difficult to make . I know of one example. The oral version of glyx-13( nrx-1074 iirc) which a few tried to make and failed . Which is good since the non oral version failed fantastically at the phase 3 trials
that's absolutely true, i can't deny that. my experience is mostly with cathinones, phenethylamines, and a few substituted amphetamines. oh, and some tryptamines.
India has been pretty open and vocal about ignoring pharma patents when it comes to medications. They put the needs of the people above the financial wants of the industry.
It's been a cause of tension in trade negotiations.
If anyone is interested in a talk by one of the authors (Kevin Strange), he goes into the history of the compound here: https://www.youtube.com/watch?v=6aAr5pKW9Dw
For progress on similar lines of tech, this is a good site: https://www.lifespan.io/the-rejuvenation-roadmap/